No Data
Weight loss candidate drug nimacimab safety approved. Skye (SKYE.US) stock price soared 11%.
Skye Bioscience's stock price soared 11%, benefiting from the safety differences between its weight loss candidate drug nimacimab and novo-nordisk a/s's monlunabant.
Sector Update: Health Care Stocks Retreat Late Afternoon
Skye Stock Rallies 22% Following Weight-loss Drug Update
Structure Therapeutics Shares Are Trading Higher After Morgan Stanley Initiated Coverage on the Stock With an Overweight Rating and Announced a $118 Price Target.
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Cantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
I Am 102927471 :